Difficult-to-Treat Migraine: Recent Developments and Management

Program Dates: October 21, 2020 - October 20, 2021
Credits: 1.0 AMA PRA Category 1 Credit™

Difficult-to-Treat Migraine: Recent Developments and Management

Program Overview

This CME program is enduring material from a symposium given by Dr. Teshamae Monteith at the Florida Society of Neurology 2020 Virtual Meeting hosted on October 3, 2020 regarding difficult-to-treat migraine. Dr. Monteith covers the diagnosis of migraine and the impact this can have on the patient as well as social determinants and risk factors for migraine. Recent clinical trials and treatment strategies are reviewed to ensure best practices with treatment. The impact of the COVID19 pandemic on treatment options will also be covered. After participating in this program, clinicians will be able to optimize their treatment of their patients with migraine.

Target Audience

The target audience includes neurologists, internists and other clinicians, including nurses, NPs, and PAs who manage patients with Migraine


I. Scientific Advances on the Pathophysiology of Migraine

II. The Development of Novel Therapeutics: Antibodies Against Calcitonin Gene-Related Peptide (CGRP)

III. The Latest Guidelines and Recommendations to Improve the Management of Patients with Migraine

Learning Objectives

  1. Review the impact and diagnosis of migraine and migraine subtypes.
  2. Evaluate the role of social determinants and risk factors for migraine progression.
  3. Analyze latest scientific data on efficacy, safety and tolerability of novel antibodies to the calcitonin gene-related peptide (CGRP) and its receptor.
  4. Discuss cases and incorporate guidelines on treatment strategies to effectively manage difficult-to-treat migraine and overcome potential clinical pitfalls.
  5. Review acute treatment of migraine attacks and newer non-vasoconstrictive options.
  6. Discuss management of migraine in the era of the COVID19 pandemic and the use of telemedicine for headache disorders.


Teshamae Monteith

Teshamae Monteith, MD, FAHS, FAAN
Associate Professor of Clinical Neurology
University of Miami, Miller School of Medicine
Chief, Headache Divsion
Florida Neurological Society




Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Teshamae Monteith, MD, FAHS, FAAN Consultant/Advisor: Amgen Inc.; Alder Biopharmaceuticals; ElectroCore Inc.; Biohaven Pharmaceuticals

Grant/Research Support: Amgen Inc.; Electrocore Inc.; Novartis International AG; Teva Pharmaceuticals; Eli Lilly and Co.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.


Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM

Financial Support

This activity has been supported by an independent educational grant from Amgen, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].